肺栓塞的里瓦洛克萨班治疗引起的自发性血胸:一个病例报告
Bassem Al Hariri1,2, Ahmad Taher Alharafsheh3, Muad Abdi Hassan4
1Department of Medicine Hamad Medical Corporation Doha Qatar.
Clinical case reports
|December 13, 2023
概括
直接口服抗凝剂 (DOAC),如利瓦洛克萨班,可能与自发性血胸病有关. 这项案例研究强调了肺栓塞治疗后的潜在风险.
科学领域:
- 医学 医学 医学 医学 医学
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
背景情况:
- 血胸病是一种罕见的疾病,涉及到腔空间的血液,可能危及生命.
- 常见的原因包括创伤,手术和某些药物.
- 自发性血胸与诸如肺梗塞等疾病有关.
研究的目的:
- 调查直接口服抗凝剂 (DOAC) 与自发性血胸之间的潜在关联.
- 检查一个特定的案例,将里瓦罗克萨班使用与肺栓塞治疗后自发性血胸病联系起来.
主要方法:
- 案例报告分析.案例报告分析.
- 关于抗凝剂相关的血胸病的文献综述.
主要成果:
- 一名患者在开始治疗肺栓塞的里瓦罗克萨班后出现了自发的血胸.
- 这表明DOAC治疗的潜在并发症,虽然很少见.
结论:
- 里瓦罗克萨班的使用可能与自发性血胸有关.
- 需要进一步的研究来证实这种关联,并了解潜在的机制.
相关概念视频
Disorders of Hemostasis
922
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
922
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Pneumothorax-II
156
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
156
Esophageal Varices-I: Introduction
149
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
149
Pneumothorax-I
212
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
212
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


